These gaps in mucosal immunity, particularly a lack of mucosal neutralizing antibodies and IgA responses, likely contribute to high rates of breakthrough infections with Omicron variants, highlighting the urgency for effective mucosal COVID-19 vaccines. This evidence concerns the gene CD79A and infection.